Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
NAD⁺ & NMN
Research brief

PTSD and anxiety genetic study links aging pathways to synaptic vulnerability

A transcriptome-wide association study using genetic summary data found aging-related pathway signals shared by anxiety disorders and PTSD, plus disorder-specific patterns; subtype labels remain proposed hypotheses. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The study used large-scale genome-wide association study summary statistics for anxiety disorders and PTSD and focused on curated aging-related pathways in brain regions for fear, reward, memory and stress regulation. [1]

  2. PTSD showed a distinctive negative signature in NAD metabolism and sirtuin-related pathways, most prominently driven by SIRT3, with evidence of SARM1-linked axonal and synaptic vulnerability. [1]

  3. The authors state that the subtype labels are proposed biological hypotheses rather than validated clinical categories. [1]

The source at a glance

Study type / format
Multi-gene-set transcriptome-wide association study using GWAS summary statistics (abstract)
Population / context
Genetic summary statistics for anxiety disorders and PTSD, analyzed across brain regions involved in fear, reward, memory and stress regulation.
Summary based on
Study abstract
Original publication
June 12, 2026

Genetic summary data across fear and stress brain regions

The researchers ran a multi-gene-set transcriptome-wide association study. It used large-scale genome-wide association study summary statistics for anxiety disorders and PTSD and focused on curated aging-related pathways in brain regions involved in fear, reward, memory and stress regulation. This is an association-based analysis of genetic summary data, not a study of patients followed over time.

Supporting source [1]

Shared senescence signals, distinct NAD and sirtuin pattern in PTSD

The analysis identified 185 significant enrichments, with strong concordance across both disorders in senescence, telomere maintenance and mitochondrial modules. PTSD showed a distinctive negative signature in nicotinamide adenine dinucleotide (NAD) metabolism and sirtuin-related pathways, most prominently driven by sirtuin 3 (SIRT3), plus evidence of SARM1-linked axonal and synaptic vulnerability. Anxiety disorders showed stronger enrichment in mitochondrial intrinsic apoptosis and inflammatory-redox signaling, alongside glutamatergic and astrocytic plasticity changes. Both shared senescence and DNA-damage programs, with NEK4 as a common driver.

Supporting source [1]

Proposed subtypes, not validated clinical categories

The pathways converged on complement-mediated pruning and presynaptic remodeling, which the authors describe as a possible mechanistic bridge from cellular aging to fear and reward circuit dysfunction. They frame this as an association-based model in which genetic liability for anxiety disorders and PTSD converges on stress-aging biology at the synapse while diverging by disorder. The authors state that the subtype labels are proposed biological hypotheses rather than validated clinical categories.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. This is an association-based analysis of genetic summary statistics, so it cannot show causation, and the proposed subtypes are not validated clinical categories.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    using large-scale genome-wide association study (GWAS) summary
  2. Finding 2 ↑

    PTSD showed a distinctive negative signature in
  3. Finding 3 ↑

    proposed biological hypotheses rather than validated clinical

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…